Review · United States
Retatrutide
Reviewed on
Approval and product status
Still being studied in the United States; no FDA-approved retatrutide product
A product sold under the same name may not match the product used in trials. Retatrutide is still being studied. A study product made under a study protocol does not prove that products sold online under the same name have the same identity or quality.
What was measured in people?
- Health results · Moderate
- A full phase 2 report and several early phase 3 sponsor reports show meaningful results in people. Full reports for the phase 3 studies and FDA review are not complete.
- Body changes · Moderate
- Human dose-response and adverse-event data exist, but the development program is not complete.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
An investigational molecule is not a self-treatment category. This guide does not provide trial-drug access, sourcing, dosing, injection, or combination instructions.
Still unknown: These announcements are early summaries from the study sponsor. They do not replace full reports checked by other experts or FDA review. Retatrutide is still being studied, and other outcome programs remain active. Current records do not show its long-term balance of possible benefits and harms, rare harms, broad real-world effectiveness, or whether products sold outside clinical trials have the same identity.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Approval fact checks
“Retatrutide is FDA-approved.”
Misleading. It remains investigational. FDA says retatrutide is not a component of an approved drug and has not been found safe and effective for any condition. Positive trial results and sponsor announcements are not marketing approval.
Applies to: United States regulatory status as reviewed August 1, 2026.
“Retatrutide is being submitted to FDA, so it will be available in 2027.”
Misleading. Lilly states it plans to submit retatrutide for obesity in the first quarter of 2027. A planned submission is a future corporate action, not regulatory acceptance, approval, a prescribing label, or a launch date. Until an approval is recorded by the regulator, the accurate U.S. status remains investigational.
Applies to: The sponsor-stated first-quarter 2027 U.S. submission plan as reviewed August 1, 2026.
Products in this review
These are selected records, not every product or form.
No product label record is included here. That is not a separate approval decision. Read the status and sources above.
What the research shows
In a 48-week phase 2 study, people were assigned to groups by chance. Higher study doses were linked to more weight reduction. Lilly announced early sponsor-reported TRIUMPH-1 results in May 2026. It announced early sponsor-reported TRIUMPH-2 and TRIUMPH-3 results in July 2026. These studies covered specific groups of people with obesity. Some groups had type 2 diabetes or established cardiovascular disease, and some did not.
Read all Retatrutide fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 11 sources
- LY3437943 in people with type 2 diabetes: a phase 1b randomized trial
PubMed · The Lancet · Human pharmacology · 2022
Source accessed
- Retatrutide for people with type 2 diabetes: a phase 2 randomized trial
PubMed · The Lancet · Randomized trial · 2023
Source accessed
- Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial
PubMed · New England Journal of Medicine · Randomized trial · 2023
Source accessed
- Retatrutide for metabolic dysfunction-associated steatotic liver disease
PubMed · Nature Medicine · Randomized trial · 2024
Source accessed
- TRIUMPH-1 phase 3 study record
ClinicalTrials.gov · Trial registry · 2026
Source accessed
- TRIUMPH-2 phase 3 study record
ClinicalTrials.gov · Trial registry · 2026
Source accessed
- TRIUMPH-3 phase 3 study record
ClinicalTrials.gov · Trial registry · 2026
Source accessed
- TRIUMPH-1 early sponsor-reported results
Eli Lilly and Company · Reference · 2026
Source accessed
- TRIUMPH-2 and TRIUMPH-3 early sponsor-reported results
Eli Lilly and Company · Reference · 2026
Source accessed
- FDA concerns with unapproved GLP-1 drugs used for weight loss
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed
- Drug approvals and databases
U.S. Food and Drug Administration · Regulatory · 2026
Source accessed